Dren Bio Partners with Novartis to Discover and Develop Novel Targeted Myeloid Engagers for Cancer
Shots:
- Novartis and Dren Bio have signed a strategic collaboration to discover and develop therapeutic bispecific antibodies for cancer treatment
- The collaboration will leverage Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform for advancing targeted myeloid engager programs. Novartis will carry out development, manufacturing, regulatory, and commercialization activities post selection
- As per the agreement, Dren Bio is entitled to receive a total $150M upfront ($25M equity), $2.85B preclinical, clinical, regulatory & commercial milestones plus tiered royalties
Ref: Dren Bio | Image: Dren Bio & Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
